Selection of Muscle Relaxant With Prior Syncope and Atrial Fibrillation
Baclofen is the safest among common oral skeletal muscle relaxants for a patient with a history of syncope and atrial fibrillation because it has no class-level QT-prolongation warning and has relatively low-frequency cardiovascular adverse effects. [1] Tizanidine and cyclobenzaprine should be avoided because both can precipitate hypotension/bradycardia and syncope, and cyclobenzaprine has QT-proarrhythmia risk. [2], [3]
Medication Selection Algorithm
- Preferred option: baclofen (Lioresal). [1]
- Avoid: tizanidine (Zanaflex) due to hypotension, bradycardia, excessive sedation, and reported syncope. [2]
- Avoid: cyclobenzaprine due to cardiovascular adverse reactions including syncope and arrhythmia, with torsade/QT prolongation risk in drug-interaction contexts. [3], [4]
- Avoid or use only with strong clinical justification: methocarbamol due to reported cardiovascular adverse reactions including bradycardia, hypotension, and syncope. [5]
Key Evidence Supporting This Recommendation
- Tizanidine prescribing information reports that adverse reactions such as hypotension and bradycardia can occur, and syncope has been reported in the postmarketing setting. [2]
- Cyclobenzaprine prescribing information lists syncope and arrhythmia among cardiovascular adverse reactions. [3]
- Baclofen prescribing information reports hypotension (0% to 9%) and rare syncope. [1]
Monotherapy Versus Combination Therapy
Skeletal muscle relaxants should be used as monotherapy when possible because additive sedation and orthostatic effects increase syncope/fall risk. [6] Combination use should be limited to situations with a clear indication because skeletal muscle relaxants are included among CNS-active drugs associated with increased fall risk in older adults. [6]
Important Clarifications and Nuances
- All oral muscle relaxants can increase dizziness or sedation, which can worsen syncope risk even when direct arrhythmia/QT risk is lower. [1], [2], [3]
- Tizanidine has clinically important drug–drug interactions mediated by CYP1A2 inhibition that increase risk of hypotension and bradycardia. [2]
Initiation Thresholds
No validated syncope- or atrial fibrillation–specific initiation threshold exists for muscle relaxant selection in major guidance documents. [2], [3]
Common Pitfalls to Avoid
- Use of tizanidine in settings predisposing to low blood pressure is a common pitfall because hypotension and bradycardia can occur and syncope has been reported. [2]
- Use of cyclobenzaprine in patients with additional QT-prolonging risks is a pitfall because cyclobenzaprine has torsade/QT-prolongation risk in reported interaction scenarios. [4]
- Use of methocarbamol without cardiovascular risk consideration is a pitfall because bradycardia, hypotension, and syncope are listed adverse reactions. [5]
Targets or Goals of Therapy
The goal is short-duration symptom control with the lowest effective dose to minimize sedation, dizziness, and blood pressure–lowering effects that can precipitate recurrent syncope. [1], [2]